Taysha Gene Therapies is trading 10.6% lower at $3.70; no clear company-specific announcement explains the October 13 decline.
- Its investor-relations release list shows the latest release was an October 2 inducement-grant announcement, not October 13 news.
- The supplied sector context shows XBI down 2.01% while major indexes were nearly flat. Biotech weakness may be contributing, but does not establish the cause of the larger stock decline.